Project Horizon

Hydrogel Injectable Depot System for Next-Generation Long-Acting HIV Prevention and Contraception: Project Horizon

The objective of Project Horizon, funded by NIH/NIAID, is to develop preclinically a systemic, long-acting, multipurpose prevention technology (MPT) incorporating both effective contraceptive and HIV prevention agents, while integrating characteristics preferred by target end-users in a US cohort.

Under an initial R61 phase, a first generation long-acting MPT injectable hydrogel depot was developed using dolutegravir, an HIV integrase inhibitor and levonorgestrel, a potent hormonal contraceptive. Under the ongoing R33 phase of Project Horizon, a more clinically relevant depot formulation, designed for co-delivery of levonorgestrel with the clinically proven, integrase inhibitor cabotegravir, has been selected for continued development. Activities supporting this development include:

Research reported on this webpage was supported by the National Institutes of Health under award number R33AI142685.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Back to top